Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
GAITHERSBURG, Md., April 04, 2016 -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Iksung Cho has been named Vice President, Biostatistics.
Mr. Cho joined Novavax in December 2015 as Executive Director, Biostatistics with responsibility for coordinating statistical and statistical programming activities for vaccine candidates in various stages of clinical development. Prior to joining Novavax he was Senior Statistician at PATH, an international nonprofit organization that aims to accelerate innovation across vaccines, drugs, diagnostics, devices and system and service innovations.
Mr. Cho’s experience includes positions of increasing responsibility in biostatistics and data management at Aviron, Merck and MedImmune, where he was Vice President of Global Biostatistics. He earned Master’s degrees in both statistics and applied mathematics from Virginia Polytechnic and State University and completed graduate studies in mathematics.
“Iksung has rapidly become a critical part of our team,” said Gregory M. Glenn, M.D., President, Research and Development. “We expect to leverage his deep experience in biostatistics to evaluate important data readouts from the pivotal Phase 3 Resolve trial of our RSV F Vaccine in older adults and the Phase 2 rollover trial in older adults later this year.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
